Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(4):242-243; doi:10.1093/jnci/94.4.242
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sporn, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sporn, M. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 4, 242-243, February 20, 2002
© 2002 Oxford University Press

EDITORIAL

Hobson's Choice and the Need for Combinations of New Agents for the Prevention and Treatment of Breast Cancer

Michael B. Sporn

Correspondence to: Michael B. Sporn, Department of Pharmacology, Dartmouth Medical School, Remsen 524, Hanover, NH 03755 (e-mail: Michael. Sporn@Dartmouth.edu).

The excellent article by O'Regan, Jordan, and colleagues in this issue of the Journal (1) highlights the "Hobson's Choice" currently available for clinical prevention or treatment of early breast cancer. In the 1600s, Thomas Hobson ran a large stable and rented horses at Cambridge University. He compelled customers to rent the one horse that happened to be nearest the stable door or go without—hence the term "Hobson's Choice." In current parlance, it has the connotation of an apparently free choice when there is no real alternative. Presently, we are faced with the clinical equivalent of a Hobson's Choice if we wish to use more than one experimental drug for prevention or adjuvant treatment of early breast cancer. In spite of numerous animal studies that indicate that treatment with combinations of two or more drugs is most effective, our current clinical . . . [Full Text of this Article]

NOTES

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C. J. Fabian and B. F. Kimler
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. B. Sporn
Arzoxifene: A Promising New Selective Estrogen Receptor Modulator for Clinical Chemoprevention of Breast Cancer: Commentary re C. J. Fabian et al., Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator. Clin Cancer Res 2004;10:5403-17.
Clin. Cancer Res., August 15, 2004; 10(16): 5313 - 5315.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
M. H. Rendi, N. Suh, W. W. Lamph, S. Krajewski, J. C. Reed, R. A. Heyman, A. Berchuck, K. Liby, R. Risingsong, D. B. Royce, et al.
The Selective Estrogen Receptor Modulator Arzoxifene and the Rexinoid LG100268 Cooperate to Promote Transforming Growth Factor {beta}-Dependent Apoptosis in Breast Cancer
Cancer Res., May 15, 2004; 64(10): 3566 - 3571.
[Abstract] [Full Text] [PDF]